Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Aurora Daljit Singh 2. Issuer Name and Ticker or Trading Symbol Neumora Therapeutics, Inc. [NMRA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O NEUMORA THERAPEUTICS, INC., 260 ARSENAL PLACE, SUITE 1 3. Date of Earliest Transaction (Month/Day/Year) 08/17/2026 (Street) WATERTOWN, MA 02472 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/17/2026 M 40,890 A $0.72 123,660 D Common Stock 08/17/2026 M 15,355 A $0.72 139,015 D Common Stock 08/17/2026 M 1,424 A $0.72 140,439 D Common Stock 08/17/2026 M 1 A $0.72 140,440 D Common Stock 08/17/2026 S 57,670 D $1.5055(1) 82,770 D Common Stock 08/17/2026 S 34,020 D $1.4853(2) 48,750 D Common Stock 08/17/2026 M 25,279 A $0.72 25,279 I See footnote(3) Common Stock 08/17/2026 M 29,737 A $0.72 55,016 I See footnote(3) Common Stock 08/17/2026 S 55,016 D $1.5047(4) 0 I See footnote(3) Common Stock 08/18/2026 M 34,162 A $0.72 82,912 D Common Stock 08/18/2026 S 34,162 D $1.5847(9) 48,750 D Common Stock 08/18/2026 M 34,987 A $0.72 34,987 I See footnote(3) Common Stock 08/18/2026 S 34,987 D $1.5859(10) 0 I See footnote(3) Common Stock 08/19/2026 M 13,268 A $0.72 62,018 D Common Stock 08/19/2026 M 17,732 A $0.72 79,750 D Common Stock 08/19/2026 S 31,000 D $1.6461(11) 48,750 D Common Stock 08/19/2026 M 30,918 A $0.72 30,918 I See footnote(3) Common Stock 08/19/2026 S 30,918 D $1.6459(12) 0 I See footnote(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.72	08/17/2026		M			40,890	(5)	09/20/2031	Common Stock	40,890	$ 0	0	D
Stock Option (Right to Buy)	$0.72	08/17/2026		M			15,355	(6)	01/19/2033	Common Stock	15,355	$ 0	192,546	D
Stock Option (Right to Buy)	$0.72	08/17/2026		M			1,424	(7)	06/23/2033	Common Stock	1,424	$ 0	70,797	D
Stock Option (Right to Buy)	$0.72	08/17/2026		M			1	(8)	02/13/2035	Common Stock	1	$ 0	999,999	D
Stock Option (Right to Buy)	$0.72	08/17/2026		M			25,279	(5)	01/19/2033	Common Stock	25,279	$ 0	110,931	I	See footnote(3)
Stock Option (Right to Buy)	$0.72	08/17/2026		M			29,737	(5)	06/23/2033	Common Stock	29,737	$ 0	0	I	See footnote(3)
Stock Option (Right to Buy)	$0.72	08/18/2026		M			34,162	(7)	06/23/2033	Common Stock	34,162	$ 0	36,635	D
Stock Option (Right to Buy)	$0.72	08/18/2026		M			34,987	(5)	01/19/2033	Common Stock	34,987	$ 0	75,944	I	See footnote(3)
Stock Option (Right to Buy)	$0.72	08/19/2026		M			13,268	(7)	06/23/2033	Common Stock	13,268	$ 0	23,367	D
Stock Option (Right to Buy)	$0.72	08/19/2026		M			17,732	(13)	02/14/2034	Common Stock	17,732	$ 0	177,268	D
Stock Option (Right to Buy)	$0.72	08/19/2026		M			30,918	(5)	01/19/2033	Common Stock	30,918	$ 0	45,026	I	See footnote(3)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Aurora Daljit Singh C/O NEUMORA THERAPEUTICS, INC. 260 ARSENAL PLACE, SUITE 1 WATERTOWN, MA 02472			See Remarks

Signatures

/s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora		08/19/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(2)	This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(3)	Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
(4)	This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(5)	The stock option is fully vested and exercisable.
(6)	25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
(7)	25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
(8)	25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
(9)	This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(10)	This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(11)	This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(12)	This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(13)	25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Remarks: Title: Chief Operating and Development Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.